Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ArthoCare Inks Deal With Justice, Cooperates Against Former Execs

This article was originally published in The Gray Sheet

Executive Summary

The company will pay $30 million, establish a compliance program and cooperate on prosecutions of former executives as part of its resolution of fraud allegations with the Department of Justice. Penalties for ArthroCare were reduced for “extraordinary” cooperation with the feds.

You may also be interested in...

Ex-ArthroCare Chiefs Convicted Of Orchestrating Fraud

The former top leaders of ArthroCare have been convicted for working in cahoots with distributors to overstate ArthroCare’s earnings. Both face significant prison time for their roles in the scam, according to the Department of Justice.

ArthroCare Bid Signals Ortho Consolidation

If completed, Smith & Nephew’s acquisition of ArthroCare would help it diversify into the ENT market, but the deal may not get done as analysts speculate that competitors Stryker and J&J could step in with counteroffers. The interest surrounding ArthroCare emphasizes the pressures being put on large joint makers to find new ways of making money in orthopedics.

Smith & Nephew Bets On RF Platform With $1.7 Bil. ArthroCare Acquisition

S&N highlighted complements between ArthroCare’s Coblation platform for resection procedures and S&N’s mechanical resection blade, among other synergies. The deal comes soon after ArthroCare settled a fraud investigation with the Department of Justice.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts